The guideline for the managements of rapidly progressive glomerulonephritis

Japanese Journal of Nephrology

Volumn 44, Issue 2, 2002, Pages 55-82

  Sakai, Hideto ^a   Kurokawa, Kiyoshi ^a   Koyama, Akio ^a   Arimura, Yoshihiro ^a   Kida, Hiroshi ^a   Shigematsu, Hidekazu ^a   Suzuki, Satoshi ^a   Nihei, Hiroshi ^a   Makino, Hirofumi ^a   Ueda, Naohiko ^a   Kawamura, Tetsuya ^a   Gejyo, Fumitake ^a   Saito, Takao ^a   Harada, Takashi ^a   Hiki, Yoshiyuki ^a   Yoshida, Masahura ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY;

ADULT; AGED; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; FEMALE; GLOMERULONEPHRITIS; GLOMERULUS BASEMENT MEMBRANE; HUMAN; MALE; PLASMAPHERESIS; REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME; VASCULITIS; ACUTE DISEASE; ARTICLE; CLASSIFICATION; DISEASE COURSE; HOSPITALIZATION; JAPAN; MIDDLE AGED; PRACTICE GUIDELINE; PROGNOSIS; SYNDROME;

ACUTE DISEASE; ADULT; AGED; DISEASE PROGRESSION; FEMALE; GLOMERULONEPHRITIS; HUMANS; JAPAN; MALE; MIDDLE AGED; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SYNDROME;

EID: 0036239251     PISSN: 03852385     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Classification of glomerular disease
2. Analysis of risk factors for patient and renal survival in crescentic glomerulonephritis
3. Long-term treatment and prognosis of rapidly progressive glomerulonephritis
4. Rapidly progressive glomerulonephritis: Analysis of prevalence and clinical course
5. Rapidly progressive glomerulonephritis: What should be first-line therapy?
6. Does truly 'idiopathic' crescentic glomerulonephritis exist?
7. Etiologies and outcome of acute renal insufficiency in older adults: A renal biopsy study of 259 cases
8. Crescentic glomerulonephritis
9. Segmental necrotizing glomerulonephritis with antineutrophil antibody: Possible arbovirus aetiology?
10. Anti-neutrophic cytoplasmic autoantibodies with specificity for myeloperoxydase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis
11. Circulating anti-neutrophil cytoplasm antibodies in patients with rapidly progressive glomerulonephritis and extracapillary proliferation
12. Antipreteinase 3- and antimyeloperoxidase-associated vasculitis
13. Pathophysiology of ANCA-associated glomerulonephritis
14. Immunopathogenesis of crescentic glomerulonephritis
15. Glomerulointerstitial events in rapidly progressive nephritic syndrome, with special reference to histologic grade and stage on renal lesions
16. Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis
17. Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement
18. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization
19. Disease spectrum of patients with antineutrophil cytoplasmic autoantibodies of defined specificities: Distinct differences between patients with anti-proteinase 3 and anti-myeloperoxidase autoantibodies
20. Management of idiopathic crescentic and diffuse proliferative glomerulonephritis: Evidence-based recommendations
21. Introduction
22. Idiopathic rapidly progressive glomerulonephritis
23. Methylprednisolone therapy for acute crescentic rapidly progressive glomerulonephritis
24. Methylprednisolone pulse therapy in two clinical types of crescentic glomerulonephritis
25. Cyclophosphamide therapy of severe systemic necrotizing vasculitis
26. Segmental necrotizing glomerulonephritis: Diagnostic, prognostic, and therapeutic significance
27. Combined cyclophosphamide and corticosteroid-induced remission in severe glomerulopathy associated with systemic vasculitis
28. Long-term follow-up after treatment of polyarteritis nodosa and Churg-Strauss angiitis with comparison of steroids, plasma exchange and cyclophosphamide to steroids and plasma exchange. A prospective randomized trial of 71 patients
29. Long-term follow-up of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: Analysis of four prospective trials including 278 patients
30. Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis
31. Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis
32. Treatment of Wegener's granulomatosis: Time to change the standard of care?
33. Methylprednisolone and cyclophosphamide pulse therapy in crescentic glomerulonephritis: Safety and effectiveness
34. Intravenous pulse cyclophosphamide therapy of crescentic glomerulonephritis
35. Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis
36. Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: A prospective, randomized study
37. Monthly cyclophosphamide pulses in the treatment of crescentic glomerulonephritis
38. Treatment of antineutrophil cytoplasm autoantibody-associated systemic vasculitis: Initiatives of the European community systemic vasculitis clinical study group
39. ANCA-associated small vessel vasculitis
40. Treatment of antineutrophil cytoplasmic autoantibody-positive systemic vasculitis and glomerulonephritis with pooled intravenous gammaglobulin
41. Treatment of Wegener's granulomatosis with intravenous immunoglobulin
42. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity
43. Low-dose intermittent trimethoprim-sulfamethoxazole for prevention of Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection
44. Intermittent trimethoprim sulfamethoxazole compared with dapsone-pyrimethamine for the simultaneous primary prophylaxis of Pneumocystis pneumonia and toxoplasmosis in patients infected with HIV
45. Disease spectrum of patients with antineutrophil cytoplasmic autoantibodies of defined specificity: Distinct differences between patients with anti-proteinase 3 and antimyeloperoxidase autoantibodies
46. The use of alkylating agents in the treatment of Wegener's granulomatosis
47. Wegener granulomatosis: An analysis of 158 patients
48. The treatment of Wegener's granulomatosis with glucocorticoids and methotrexate
49. Trimethoprim-sulfamethoxazole(co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis
50. Anti-glomerular basement membrane antibody-induced glomerulonephritis
51. Plasma exchange in Goodpasture's syndrome
52. Clinical and morphological aspects of the management of crescentic anti-glomerular basement membrane antibody (anti-GBM)nephritis/Goodpasture's syndrome
53. Therapy of anti-glomerular basement membrane antibody disease: Analysis of prognostic significance of clinical, pathologic and treatment factors
54. Goodpasture's syndrome